Tofacitinib
Tofacitinib 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Ulcerative Colitis。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
9 项
已进入 III/IV 期
10 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Takeda
- Shaikh Zayed Hospital, Lahore
- Lahore General Hospital
- All India Institute of Medical Sciences, Bhubaneswar
- Charite University, Berlin, Germany
- University of Alabama at Birmingham
- The First Affiliated Hospital of Xiamen University
- University Hospital, Toulouse
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
Pakistan、India、德国、美国、加拿大、中国、法国、西班牙、South Korea、Singapore
正在招募患者的 Tofacitinib 研究
Major Adverse Cardiovascular Events (MACE) in Rheumatoid Arthritis Patient With Moderate to Severe Disease Activity Treated With Tofacitinib and Statins vs TNF Inhibitors: TOFSTAT CLINICAL TRIAL
IV 期招募中PakistanNCT07554820Comparison Between Oral Methotrexate and Tofacitinib in Chronic Plaque Psoriasis
早期 I 期招募中PakistanNCT07261306Evaluation of Efficacy and Safety of add-on Tofacitinib in Patients With Oral Lichen Planus
IV 期招募中IndiaNCT07131813ToFAcitinib in Early Active Axial SpondyloarThritis:
IV 期招募中德国NCT06112665RA-PRO PRAGMATIC TRIAL
III 期招募中美国加拿大NCT04692493Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease
II 期招募中中国NCT07547930JAK Inhibitor Dose TAPering Strategy Study
IV 期招募中法国NCT06687551Methotrexate Combined With Tofacitinib in Rheumatoid Arthritis
不适用招募中中国NCT06301373Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease
II 期招募中美国NCT07281456Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
II 期招募中美国NCT07138898A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA
II 期招募中美国NCT06698822Tofacitinib in Juvenile Idiopathic Arthritis
不适用招募中西班牙NCT07211932Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma
II 期招募中中国NCT05348213Impact of Anti-TNF, Vedolizumab and Tofacitinib on Aortic Stiffness, Carotid Intima-media Thickness and Cardiovascular Risk of Patients With Ulcerative Colitis
IV 期招募中法国NCT04743518The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea
不适用招募中中国NCT07343635Korean College of Rheumatology Biologics and Targeted Therapy Registry
不适用招募中South KoreaNCT01965132Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
III 期招募中美国NCT03414502PsoBest - The German Psoriasis Registry
不适用招募中德国NCT01848028Ibd CAncer and seRious Infections in France (I-CARE 2)
不适用招募中法国NCT06089590Advanced Therapeutics in Rheumatoid Arthritis (RA)
IV 期招募中加拿大NCT03976245Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis
III 期招募中法国NCT04871191Modulation of the Immune System in Down Syndrome for Improved Outcomes and Neurodevelopment - 1
II 期招募中美国NCT07598643Treatment Response in Immune-mediated Myositis Associated Rapidly-progressing Interstitial Lung Disease
不适用招募中SingaporeNCT07775235A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial Lung Disease Associated With Antisynthetase Syndrome
不适用招募中中国NCT07406932
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。